Substance P, mast cells and basophils are involved in acute chest syndrome in sickle cell disease

This study identifies a novel pathogenic mechanism in sickle cell disease where substance P triggers acute chest syndrome by activating and recruiting mast cells and basophils to the lungs, leading to lethal inflammation and pain.

The Gist

Imagine your body as a bustling city. In people with Sickle Cell Disease (SCD), the red blood cells are like misshapen, sticky delivery trucks that get stuck in the narrow streets (blood vessels), causing traffic jams. These jams cause pain and damage, a condition known as a "crisis."

One of the most dangerous traffic jams happens in the lungs, called Acute Chest Syndrome (ACS). It's like a sudden, massive gridlock that can shut down the city's power plant (oxygen exchange), leading to life-threatening situations.

For a long time, doctors knew that a chemical called Substance P was high in these patients during a crisis, and they knew it caused pain. But they didn't know where it was coming from or why it was causing such a disaster in the lungs.

This paper is like a detective story that finally solves the mystery. Here is the simple breakdown of what the researchers found:

1. The Culprits: The "Alarm Bells" of the Body

The researchers discovered that the real troublemakers aren't just the stuck trucks (sickle cells), but two specific types of immune cells: Mast Cells and Basophils.

Think of Mast Cells and Basophils as the city's fire alarms and sprinkler systems. In a healthy person, they only go off when there's a real fire (like an allergy or an infection). But in SCD patients, these alarms are broken and hyper-sensitive. They are constantly buzzing, even when there is no fire.

2. The Chain Reaction: A Vicious Cycle

Here is how the disaster unfolds, step-by-step:

• The Trigger: Something happens (like low oxygen or stress), and the broken alarms (Mast Cells/Basophils) go off.
• The Explosion: When they go off, they release a massive amount of Substance P. Imagine Substance P as a super-charged "panic signal."
• The Feedback Loop: This panic signal doesn't just tell the body to feel pain; it actually tells more alarms to go off! It's like a microphone too close to a speaker, creating a screeching feedback loop that gets louder and louder.
• The Lung Attack: The researchers found that this panic signal (Substance P) specifically targets the lungs. It causes the blood vessels in the lungs to leak fluid (edema) and swell up, turning the lungs into a soggy, blocked sponge. This is the Acute Chest Syndrome.

3. The Evidence: The Mouse Experiment

To prove this, the scientists used a special type of mouse that has Sickle Cell Disease.

• They injected these mice with Substance P.
• Result: The mice immediately went into severe pain, had trouble breathing, and many died with damaged lungs.
• The Control: They did the same thing to healthy mice, and nothing happened. The healthy mice were fine.
• The "Fix": They then gave the sickle mice a drug called Cromolyn (which acts like a "stabilizer" or a "duct tape" for the broken alarms). This drug stopped the Mast Cells and Basophils from exploding. When they did this, the Substance P injection no longer killed the mice or damaged their lungs.

4. The Human Connection

The researchers looked at real patients and found:

• Patients with Sickle Cell Disease have way more Basophils in their blood than healthy people.
• During a crisis, these Basophils seem to disappear from the blood and migrate into the lungs, where they cause damage.
• When they looked at the sputum (mucus) from patients having an ACS attack, the levels of Substance P were 30 times higher than normal. It was a "smoking gun" proving the alarms were going off right inside the lungs.

5. The Big Surprise: Morphine and the "Paradox"

There is a twist in the story. Doctors often use Morphine to treat the severe pain of Sickle crises. However, this study suggests Morphine might be accidentally making things worse.

• Why? Because Morphine can also trigger those broken alarms (Mast Cells and Basophils) to release more Substance P.
• It's like trying to put out a fire by pouring gasoline on it. The pain relief is real, but it might be triggering the very mechanism that causes the lung damage (ACS).

The Takeaway: What Does This Mean?

This paper changes the game in three ways:

1. New Villain: We now know that Basophils (a type of white blood cell) are major players in Sickle Cell Disease, not just Mast Cells.
2. New Mechanism: We understand that the lung damage (ACS) is driven by a runaway feedback loop of Substance P released by these cells.
3. New Hope: The study suggests that using drugs to stabilize these cells (like Cromolyn) could prevent the lung damage and save lives. It opens the door to new treatments that stop the "alarms" from going off in the first place, rather than just treating the pain after the damage is done.

In short: The body's own fire alarms are broken in Sickle Cell patients. They scream "Panic!" (Substance P), which causes the lungs to flood and fail. The solution might be to fix the alarms so they stop screaming, rather than just trying to ignore the noise.

Technical Summary

1. Problem Statement

Acute Chest Syndrome (ACS) is a leading cause of mortality and intensive care admission in patients with Sickle Cell Disease (SCD). Its pathophysiology is incompletely understood, though it is characterized by acute lung injury, edema, and inflammation.

• Known Factors: Previous studies have linked high levels of Substance P (SP) and histamine in SCD patients to pain and neurogenic inflammation. Mast cells have been implicated in SCD pathophysiology.
• Knowledge Gap: The specific origin of Substance P in SCD, its role in inducing ACS, and the potential involvement of basophils (which share functional similarities with mast cells but are circulating immune cells) have not been explored.
• Clinical Paradox: There is a long-suspected but unproven association between morphine use (a standard analgesic for SCD pain crises) and the development of ACS. Morphine is known to activate mast cells via the MRGPRX2 receptor, but the downstream effects on basophils and lung injury remain unclear.

2. Methodology

The study employed a multi-modal approach combining human clinical observations, transgenic mouse models, and in vitro experiments.

• Human Cohort (Prospective Observational Study):

  • Subjects: 225 SCD patients recruited from two French reference centers.
  • Groups: Patients were categorized into three states: Steady State (n=132), Vaso-Occlusive Crisis (VOC) without ACS (n=71), and ACS (n=30). Healthy controls were also included.
  • Measurements: Plasma Substance P levels, cellular histamine levels, histidine decarboxylase (HDC) activity, and sputum analysis (Substance P and histamine) during ACS.
  • Flow Cytometry & Sorting: Basophils were analyzed for activation markers (CD203c, CD63) and receptor expression (NK1R, MRGPRX2, CCR3, FPR1). Sorted basophils underwent gene expression analysis (RT-PCR).

• Mouse Models:

  • Subjects: Townes transgenic sickle mice (SS) and wild-type control mice (AA).
  • Induction Models:
    • Hypoxia/Reoxygenation (8% O2 for 3h).
    • Intravenous Hemin injection (70 µmol/kg).
    • Intravenous Substance P injection (dose-dependent).
    • Intraperitoneal MAR-1 injection (anti-FcεR1α antibody to activate mast cells/basophils).
  • Intervention: Pretreatment with Cromolyn (a mast cell/basophil stabilizer) to test if degranulation inhibition prevents injury.
  • Histology: Lung tissue was analyzed for edema, congestion, alveolar wall thickening, and hemorrhage. Immunohistochemistry (IHC) and immunofluorescence were used to identify mast cells (c-kit, Mcpt8) and basophils (FcεR1α).

• In Vitro Assays:

  • Degranulation: Bone marrow-derived mast cells and basophils were exposed to Substance P; degranulation was measured via avidin uptake.
  • Chemoattraction: Microchemotaxis chambers tested basophil migration toward Substance P, LPS, and histamine.
  • Receptor Blockade: Use of NK1R antagonists (Aprepitant) to confirm receptor-mediated effects.

3. Key Results

A. Clinical Findings in Humans

• Substance P Levels: Plasma Substance P was elevated in 100% of ACS patients (median 1.11 µg/L), significantly higher than in VOC patients (0.73 µg/L) and steady-state patients.
• Sputum Analysis: Substance P levels in the sputum of ACS patients were 30-fold higher than in controls or pneumonia patients, suggesting massive local release in the lungs.
• Basophil Activation:
  • Basophil counts were higher in SCD patients at steady state but decreased during VOC/ACS, suggesting recruitment from blood to tissues (lungs).
  • Circulating basophils showed increased activation (CD203c) and degranulation (CD63) markers.
  • Cellular histamine and HDC activity were elevated, confirming basophil involvement.
• Gene Expression: Sorted basophils from SCD patients overexpressed chemokine receptors CCR3 and FPR1, as well as Substance P receptors NK1R and MRGPRX2.

B. Mouse Model Findings

• Substance P Toxicity: Intravenous Substance P induced lethal crises and acute lung injury (edema, hemorrhage) in SS mice but had no effect on AA mice. Mortality was dose-dependent.
• Mechanism of Injury:
  • Activation of mast cells/basophils via MAR-1 (anti-FcεR1α) mimicked the lethal effects of Substance P.
  • Cromolyn Pretreatment: Stabilizing mast cells/basophils with cromolyn completely prevented Substance P-induced lung injury and lethality in SS mice.
• Cellular Recruitment:
  • IHC revealed the presence of mast cells and basophils in the lungs of SS mice (absent in AA mice).
  • Substance P injection increased the number of these cells in the lungs and induced degranulation.
  • Blood basophil counts in SS mice dropped after injury induction, confirming tissue recruitment.

C. In Vitro Mechanisms

• Chemoattraction: Substance P acted as a potent chemoattractant for basophils via the NK1R receptor (blocked by Aprepitant).
• Receptor Overexpression: The overexpression of NK1R and MRGPRX2 on SCD basophils creates a "vicious cycle" where Substance P (and potentially morphine) activates these cells, leading to further degranulation and Substance P release.

4. Key Contributions

1. Novel Pathophysiological Mechanism: The study identifies a specific pathway where Substance P, released by activated mast cells and basophils, drives the pathogenesis of Acute Chest Syndrome.
2. Role of Basophils: It is the first study to explicitly implicate circulating basophils in SCD pathophysiology, demonstrating their recruitment to the lungs and their contribution to lung injury via degranulation.
3. Explanation of Morphine-ACS Link: The findings provide a mechanistic explanation for the suspected link between morphine and ACS. Morphine activates basophils/mast cells via MRGPRX2, triggering Substance P release, which in turn recruits more basophils and causes lung injury.
4. Biomarker Potential: Substance P levels in sputum and plasma are proposed as specific markers for ACS, potentially aiding in distinguishing ACS from pneumonia.
5. Therapeutic Implications: The study demonstrates that stabilizing mast cells and basophils (e.g., with Cromolyn) prevents lethal lung injury in mouse models, suggesting a new therapeutic avenue for preventing ACS in humans.

5. Significance

This research fundamentally shifts the understanding of ACS from a purely hemodynamic or infectious event to an immune-mediated inflammatory process driven by the Substance P-Mast Cell/Basophil axis.

• Clinical Impact: It challenges the current management of SCD pain crises, suggesting that morphine might inadvertently exacerbate lung injury in susceptible patients by triggering this specific immune loop.
• Future Directions: It opens the door for clinical trials using mast cell/basophil stabilizers (like Cromolyn) or NK1R/MRGPRX2 antagonists to prevent ACS.
• Diagnostic Utility: Measuring Substance P in sputum could offer a rapid, specific diagnostic tool for ACS, which is currently difficult to distinguish from pneumonia.

In summary, the paper elucidates a "vicious cycle" where inflammation leads to basophil recruitment, Substance P release, and further degranulation, culminating in the acute lung injury characteristic of ACS.